Docket No. 1217-0156P

Please amend the claims as follows:

- 5°) (AMENDED) Process according to claim 2 [any one of claims 2 to 4], characterized by the fact that said hydrazine derivative group borne by the peptide is an α -hydrazinoacetic group.
- 8°) (AMENDED) Process according to <u>claim 1</u> [any one of the preceding claims], characterized in that said compound A is selected from the group constituted by lipids, sugars, alcohols and fluorescence markers.
- 11°) (AMENDED) Modified peptide, characterized in that it is essentially constituted by a peptide linked, by a hydrazide link, to at least one compound A selected from the group constituted by lipids, sugars, alcohols and fluorescence markers.
- 12°) (AMENDED) Modified peptide according to claim 11, characterized in that it is an oligopeptide essentially constituted by a peptide linked, by a hydrazide link, to at least one lipid selected from the group constituted by saturated fatty acids, unsaturated fatty acids and sterols.
- 13°) (AMENDED) Modified peptide according to claim 12, characterized in that it is an oligopeptide essentially constituted by a peptide linked, by a hydrazide link, to at least one lipid selected from the group constituted by palmitic acid,

Docket No. 1217-0156P

stearic acid, cis-9,10-epoxystearic acid, oleic acid, linoleic acid and cholesterol.

- 14°) (AMENDED) Synthetic vaccine, characterized in that it includes at least one modified peptide according to any one of claims 11 to 13.
- 15°) (AMENDED) Diagnosis reagent, characterized in that it includes at least one modified peptide according to any one of claims 11 to 13.
- 16°) (AMENDED) Use of the residue of the process according to claim 1 for the preparation of a medicament including an active principal of a vectorized peptidic nature, useful for cell targeting.
- 17°) (AMENDED) Use of N,N'-tri(Boc)hydrazinoacetic acid or of N,N'-di(Boc)hydrazinoacetic acid for functionalizing a peptide designed to be linked according to the process according to claim 5, with this taking place prior to step b), with an α^- hydrazinoacetic group, either at the N-terminal end of said peptide or at the end of the side chain of a lysine or of an ornithin possibly present at some point in the peptide sequence.

Please add the following claims:

Docket No. 1217-0156P

- --19. A method for cell targeting a peptide which comprises administering to a host a modified peptide prepared by the process according to claim 1 for the preparation of a medicament including an active principal of a vectorized peptidic nature, useful for cell targeting.—
- --20. A method for cell targeting a peptide which comprises administering to a host a modified peptide according to claim 11.--